866-997-4948(US-Canada Toll Free)

Report Package: Hot targets for empowered antibody and cell therapy technologies

Published By :

La Merie Publishing

Published Date : Dec 2016

Category :

Therapeutic Area

No. of Pages : 202 Pages

Report Package: Hot targets for empowered antibody and cell therapy technologies
This package contains three reports analyzing

BCMA,
CD123 and
CD22

as versatile and hot targets for the successful application of empowered antibody and cell technologies, including:

Fc-Engineered Antibodies;
Radioimmunotherapy;
Immunotoxins;
Antibody-Drug Conjugates;
T-Cell Redirecting Bispecific Antibodies;
Chimeric Antigen Receptor (CAR) T-Cells.

The reports describe and discuss

Target background, scientific rationale & expression profiles;
Preclinical proof-of-concept;
Clinical experience;
Competitive landscape;
Drug or cell therapy profiles;
Company profiles.

Each of the three reports can be obtained individually, but the package of the three reports provides a 40% discount on the regular prices:
B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities
CD123: a paradigmatic target for immunotherapeutic treatment modalities
CD22: a suitable antigen for targeted payload delivery by immunotherapeutics
Detailed report descriptions, tables of contents and samples from the reports can be found on the respective product page.

Report Package: Hot targets for empowered antibody and cell therapy technologies
Tables of Content
Report 1:
B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities
Target Background
Target Antigen Expression Profile
Preclinical Proof-of-Concept
Clinical Indications & Treatment Options
Clinical Experience with BCMA-Targeted Treatment Modalities
Treatment Modalities & Competitive Landscape

 

 


Drug & Cell Therapy Candidate Profiles
CAR T-Cells
Antibody-Drug Conjugate (ADC)
T-Cell Redirecting Antibodies

Company Profiles
References

 

 


 

 


Report 2:
CD123: a paradigmatic target for immunotherapeutic treatment modalities
Target Background & Scientific Rationale
Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics
Clinical Experience with CD123-Targeted Treatment Modalities
Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD123 Immunotherapeutics:

 

 


Immunotoxins
Naked Antibody
Fc-Engineered Antibodies
Antibody-Drug Conjugates
T-Cell Redirecting Bispecific Antibodies
Anti-CD123 CAR T-Cells

Company Profiles
References
ADDENDUM: Competitor Analysis of CD123-Targeted Immunotherapeutics

 

 


 

 


Report 3:
CD22: a suitable antigen for targeted payload delivery by immunotherapeutics
Target Background & Scientific Rationale
Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD22 Immunotherapeutics

 

 


Naked antibodies;
Radioimmunotherapy (RIT);
Immunotoxins (IT);
Antibody-Dug Conjugates (ADC); and
Chimeric Antigen Receptor (CAR) T-Cells.

Profiles of Companies with CD22-Targeted Immunotherapeutics
References
ADDENDUM: Competitor Analysis of of CD22-Targeted Immunotherapeutics

 

 

List of Table

NA

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *